Eli Lilly shares rise as Q3 revenue jumps 54% to $17.6 billion, earnings top estimates, and analysts lift price targets on ...

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.1% in the morning session after the ...

Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin ...

Pharmaceutical titan Eli Lilly has delivered a quarterly report that dramatically surpassed market forecasts, sending waves ...

Global pharmaceutical company Eli Lilly (NYSE:LLY) will be announcing earnings results this Thursday before market open. Here ...

Global pharmaceutical company Eli Lilly (NYSE:LLY) reported in Q3 CY2025, with sales up 53.9% year on year to $17.6 billion.

Eli Lilly (LLY) stock rises after reporting that sales of its weight-loss drugs more than doubled in the third quarter. The ...

Eli Lilly stock (NYSE: LLY) is up 7% in a month, warranting investor attention following a key corporate development. Eli ...

Eli Lilly beat Q3 estimates with $7.02 EPS and $17.60 billion revenue, raising full-year guidance as Zepbound and Mounjaro ...

Eli Lilly’s stock rallies, as Zepbound sales nearly tripled, leading to record revenue and a raised full-year outlook.

See, LLY stock warrants your attention. Why? Because it offers monopoly-like high margins at a discounted price.

October 30th is the day when Eli Lilly will report its third-quarter results, including sales of its 'superstars' Zepbound ...